About
DO YOU HAVE A FULL UNDERSTANDING OF HOW VALUATION METHODOLOGIES WILL BE AFFECTED BY PROPOSED LEGAL AND REGULATORY REFORMS?
The valuation of pharmaceutical and biotech patents has always been a complex task. However, proposed changes to the Hatch Waxman Act, and other related regulatory reforms promise to make the assessment of these patents even more complicated.
Do you have all the information that you need to determine the true worth of your company's prized life sciences patents within the context of changing laws and regulation?
This innovative
American Conference Institute publication will bring you cutting edge and practical information on valuation techniques, as well as targeted analysis and commentary on how legal and regulatory reform will affect these techniques. An outstanding faculty of financial analysts, consultants, and investment bankers, as well as counsel from the pharmaceutical and biotech industries, will walk you through the mechanics - and finer points of patent valuation and provide insights on the related reforms which are on the horizon.
About
DO YOU HAVE A FULL UNDERSTANDING OF HOW VALUATION METHODOLOGIES WILL BE AFFECTED BY PROPOSED LEGAL AND REGULATORY REFORMS?
The valuation of pharmaceutical and biotech patents has always been a complex task. However, proposed changes to the Hatch Waxman Act, and other related regulatory reforms promise to make the assessment of these patents even more complicated.
Do you have all the information that you need to determine the true worth of your company's prized life sciences patents within the context of changing laws and regulation?
This innovative
American Conference Institute publication will bring you cutting edge and practical information on valuation techniques, as well as targeted analysis and commentary on how legal and regulatory reform will affect these techniques. An outstanding faculty of financial analysts, consultants, and investment bankers, as well as counsel from the pharmaceutical and biotech industries, will walk you through the mechanics - and finer points of patent valuation and provide insights on the related reforms which are on the horizon.
Contents & Contributors
VALUING PATENT-PROTECTED BIOPHARMACEUTICAL PRODUCTS:
SALES ESTIMATES: THEY'RE CALLED ESTIMATES FOR A REASON
Michael Herman, Royalty Pharma
VALUING PATENT – PROTECTED BIOPHARMACEUTICAL PRODUCTS
Troy Norris, L.E.K. Consulting LLC
VALUATION IN BIOPHARMACEUTICALS
Daniel J. Oh, Eli Lilly and Company
Tim Opler, Credit Suisse First Boston
TAX ISSUES AFFECTING THE VALUATION OF PHARMACEUTICAL AND
BIOTECH PATENTS IN MULTI-NATIONAL COMPANIES: IT'S NOT HOW
MUCH YOU EARN, IT'S HOW MUCH YOU KEEP
George G. Korenko, Ph.D., National Economic Research Associates, Inc.
PATENT VALUATION – THE GENERIC PERSPECTIVE
Michael A. Davitz, M.D., J.D., Taro Pharmaceuticals
LEGISLATIVE, REGULATORY AND JUDICIAL DEVELOPMENTS AFFECTING
VALUATION
James Leeds, Eli Lilly and Company
Publication Details